$ADAP
Adaptimmune Therapeutics PLC

2021 Q4 Form 10-K Financial Statement

#000155837022003489 Filed on March 14, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $1.417M $6.149M $1.500M
YoY Change -5.53% 55.36% 105.48%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.78M $57.31M $13.24M
YoY Change 11.6% 25.12% 23.39%
% of Gross Profit
Research & Development $29.51M $111.1M $25.78M
YoY Change 14.45% 21.32% 26.68%
% of Gross Profit
Depreciation & Amortization $2.234M $5.630M $1.730M
YoY Change 29.13% -15.04% -17.22%
% of Gross Profit
Operating Expenses $44.28M $111.1M $39.02M
YoY Change 13.48% 21.32% 25.55%
Operating Profit -$162.2M
YoY Change 21.62%
Interest Expense $179.0K $1.101M -$1.710M
YoY Change -110.47% -54.13% -480.0%
% of Operating Profit
Other Income/Expense, Net $4.036M $3.852M $2.660M
YoY Change 51.73% 231.5% 322.22%
Pretax Income -$38.65M -$157.3M -$36.56M
YoY Change 5.71% 21.06% 24.86%
Income Tax $209.0K $791.0K $50.00K
% Of Pretax Income
Net Earnings -$38.86M -$158.1M -$36.61M
YoY Change 6.14% 21.52% 24.69%
Net Earnings / Revenue -2742.27% -2570.99% -2440.67%
Basic Earnings Per Share -$0.17
Diluted Earnings Per Share -$41.45K -$0.17 -$39.40K
COMMON SHARES
Basic Shares Outstanding 937.2M 934.8M 928.7M
Diluted Shares Outstanding 934.8M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $369.6M $369.6M $368.2M
YoY Change 0.37% 0.37% 311.22%
Cash & Equivalents $149.9M $149.9M $56.88M
Short-Term Investments $219.6M $219.6M $311.3M
Other Short-Term Assets $2.082M $11.87M $444.0K
YoY Change 368.92% 29.03% -75.46%
Inventory
Prepaid Expenses $9.043M $6.314M
Receivables $752.0K $752.0K $139.0K
Other Receivables $33.25M $33.25M $20.60M
Total Short-Term Assets $415.5M $415.5M $398.2M
YoY Change 4.35% 4.33% 230.45%
LONG-TERM ASSETS
Property, Plant & Equipment $30.49M $51.37M $27.78M
YoY Change 9.78% 10.0% -10.59%
Goodwill
YoY Change
Intangibles $1.000M $1.730M
YoY Change -42.2% -21.29%
Long-Term Investments
YoY Change
Other Assets $1.718M $1.718M $4.600M
YoY Change -62.65% -62.65% -34.29%
Total Long-Term Assets $54.09M $54.09M $52.99M
YoY Change 2.07% 2.24% -13.21%
TOTAL ASSETS
Total Short-Term Assets $415.5M $415.5M $398.2M
Total Long-Term Assets $54.09M $54.09M $52.99M
Total Assets $469.5M $469.5M $451.1M
YoY Change 4.08% 4.09% 148.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.113M $8.113M $6.389M
YoY Change 26.98% 26.77% 0.5%
Accrued Expenses $29.91M $31.90M $27.08M
YoY Change 10.45% 7.05% 15.91%
Deferred Revenue $22.20M $2.832M
YoY Change 683.86% 33.08%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $62.54M $62.54M $39.07M
YoY Change 60.06% 59.95% 13.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $673.0K $201.0M $644.0K
YoY Change 4.5% 183.96% 7.69%
Total Long-Term Liabilities $673.0K $201.0M $644.0K
YoY Change 4.5% 183.96% 7.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $62.54M $62.54M $39.07M
Total Long-Term Liabilities $673.0K $201.0M $644.0K
Total Liabilities $263.6M $263.6M $109.9M
YoY Change 139.81% 139.84% 89.82%
SHAREHOLDERS EQUITY
Retained Earnings -$743.8M -$585.8M
YoY Change 26.99% 28.55%
Common Stock $1.337M $1.325M
YoY Change 0.91% 40.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $206.0M $206.0M $341.2M
YoY Change
Total Liabilities & Shareholders Equity $469.5M $469.5M $451.1M
YoY Change 4.08% 4.09% 148.5%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$38.86M -$158.1M -$36.61M
YoY Change 6.14% 21.52% 24.69%
Depreciation, Depletion And Amortization $2.234M $5.630M $1.730M
YoY Change 29.13% -15.04% -17.22%
Cash From Operating Activities $133.9M $10.73M -$29.21M
YoY Change -558.5% -120.02% 133.12%
INVESTING ACTIVITIES
Capital Expenditures -$4.042M $8.574M -$1.240M
YoY Change 225.97% 266.25% 103.28%
Acquisitions
YoY Change
Other Investing Activities -$24.45M $84.58M $8.840M
YoY Change -376.57% -130.64% -63.62%
Cash From Investing Activities -$28.49M $75.80M $7.610M
YoY Change -474.39% -127.18% -67.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.529M
YoY Change -99.24%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 52.00K 3.288M 120.0K
YoY Change -56.67% -99.03%
NET CHANGE
Cash From Operating Activities 133.9M 10.73M -29.21M
Cash From Investing Activities -28.49M 75.80M 7.610M
Cash From Financing Activities 52.00K 3.288M 120.0K
Net Change In Cash 105.5M 90.18M -21.48M
YoY Change -591.1% 1271.38% -292.47%
FREE CASH FLOW
Cash From Operating Activities $133.9M $10.73M -$29.21M
Capital Expenditures -$4.042M $8.574M -$1.240M
Free Cash Flow $138.0M $2.155M -$27.97M
YoY Change -593.28% -103.85% 134.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
934833017
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
854783763
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
629805218
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
937547934
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001621227
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
928754958
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-37368
CY2021 dei Entity Registrant Name
EntityRegistrantName
ADAPTIMMUNE THERAPEUTICS PLC
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
60 Jubilee Avenue, Milton Park
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Abingdon, Oxfordshire
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
OX14 4RX
CY2021 dei Entity Address Country
EntityAddressCountry
GB
CY2021 dei City Area Code
CityAreaCode
44
CY2021 dei Local Phone Number
LocalPhoneNumber
1235 430000
CY2021 dei Security12b Title
Security12bTitle
American Depositary Shares, each representing
CY2021 dei Trading Symbol
TradingSymbol
ADAP
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
false
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
583895832
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
940393818
CY2021 dei Auditor Firm
AuditorFirmId
1118
CY2021 dei Auditor Name
AuditorName
KPMG LLP
CY2021 dei Auditor Location
AuditorLocation
Reading, United Kingdom
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149948000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56882000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
219632000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
311335000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
752000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
139000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
45126000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
29796000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
415458000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
398152000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1718000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4602000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20875000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18880000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
36253000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31097000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30494000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27778000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1000000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1730000
CY2021Q4 us-gaap Assets
Assets
469545000
CY2020Q4 us-gaap Assets
Assets
451142000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8113000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6389000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2320000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2773000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29909000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27079000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
22199000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2832000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62541000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
39073000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23148000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20938000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
177223000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
49260000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
673000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
644000
CY2021Q4 us-gaap Liabilities
Liabilities
263585000
CY2020Q4 us-gaap Liabilities
Liabilities
109915000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1240853520
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
937547934
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1038249630
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
928754958
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1337000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1325000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
959611000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
935706000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11142000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10048000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-743846000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-585756000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
205960000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
341227000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
469545000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
451142000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6149000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3958000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1122000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
111090000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91568000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97501000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57305000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
45795000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43391000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
168395000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
137363000
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
140892000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-162246000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-133405000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-139770000
CY2021 us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
1095000
CY2020 us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
2313000
CY2019 us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
2772000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3852000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1162000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
75000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-157299000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-129930000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-136923000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
791000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
162000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
242000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-158090000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-130092000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-137165000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
934833017
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
854783763
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
629805218
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-158090000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-130092000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-137165000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2020 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2019 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
5808000
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-19220000
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-9478000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6435000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
16364000
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11783000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-461000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
161000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
207000
CY2021 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2020 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2019 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2021 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
6000
CY2020 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
89000
CY2019 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
13000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-159184000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-132876000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-134666000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
246885000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
366000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2499000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11053000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-137165000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
123638000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
125303000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5663000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2784000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10414000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-130092000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
341227000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
759000
CY2021 adap Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
2529000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1094000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20629000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-158090000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
205960000
CY2021 us-gaap Profit Loss
ProfitLoss
-158090000
CY2020 us-gaap Profit Loss
ProfitLoss
-130092000
CY2019 us-gaap Profit Loss
ProfitLoss
-137165000
CY2021 us-gaap Depreciation
Depreciation
5630000
CY2020 us-gaap Depreciation
Depreciation
6627000
CY2019 us-gaap Depreciation
Depreciation
7172000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
937000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
967000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
838000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
20629000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
10414000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
11053000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-540000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1333000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-1076000
CY2021 adap Amortization Accretion Of Marketable Securities
AmortizationAccretionOfMarketableSecurities
5276000
CY2020 adap Amortization Accretion Of Marketable Securities
AmortizationAccretionOfMarketableSecurities
3836000
CY2019 adap Amortization Accretion Of Marketable Securities
AmortizationAccretionOfMarketableSecurities
-185000
CY2021 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
1173000
CY2020 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-55000
CY2019 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-13000
CY2021 adap Increase Decrease In Current Assets
IncreaseDecreaseInCurrentAssets
19358000
CY2020 adap Increase Decrease In Current Assets
IncreaseDecreaseInCurrentAssets
-1747000
CY2019 adap Increase Decrease In Current Assets
IncreaseDecreaseInCurrentAssets
1436000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2458000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1450000
CY2021 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
4207000
CY2020 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
3867000
CY2019 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
5508000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
149785000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
47973000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2095000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10729000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53591000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-112507000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8574000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2341000
CY2019 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1482000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
224343000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
105022000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1592000
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
207000
CY2020 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
565000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-960000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-372000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
90182000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6576000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17568000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61484000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54908000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72476000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
151666000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
139762000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
381040000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
27284000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
75800000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-278924000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
94945000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2529000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
334388000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
759000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5663000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
366000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3288000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
340051000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
366000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
365000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61484000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54908000
CY2021 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
7765000
CY2020 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
6216000
CY2019 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
3426000
CY2021 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-5276000
CY2020 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-3836000
CY2019 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
185000
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
535000
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
75000
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
201000
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1</b><b style="font-weight:bold;"> </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Adaptimmune Therapeutics plc is registered in England and Wales. Its registered office is 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom. Adaptimmune Therapeutics plc and its subsidiaries (collectively “Adaptimmune” or the “Company”) is a clinical-stage biopharmaceutical company primarily focused on providing novel cell therapies to people with cancer. The Company is </span>a leader in the development of T-cell therapies for solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage of clinical development including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical programs or clinical programs, the need to obtain marketing approval for its cell therapies, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of its cell therapies, the need to develop a reliable commercial manufacturing process, the need to commercialize any cell therapies that may be approved for marketing, and protection of proprietary technology. If the Company does not successfully commercialize any of its cell therapies<span style="white-space:pre-wrap;">, it will be unable to generate product revenue or achieve profitability. The Company had an accumulated deficit of </span>$743,846,000 as of December 31, 2021.</p>
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-743846000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b>          <b style="font-weight:bold;">Use of estimates in financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are primarily made in relation to revenue recognition, estimation of the incremental borrowing rate for operating leases, and valuation allowances relating to deferred tax assets. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p>
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2019 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149948000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56882000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1718000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4602000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
151666000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61484000
CY2021 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
224343000
CY2020 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
105022000
CY2019 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
125303000
CY2021 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
6000
CY2020 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
89000
CY2019 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
13000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
176483000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
36
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
390000
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
157985000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
30
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
158000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
35000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
4556000
CY2021 adap Reimbursement Of Research And Development Tax And Expenditure Credit
ReimbursementOfResearchAndDevelopmentTaxAndExpenditureCredit
34082000
CY2021 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
562000
CY2020 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
889000
CY2020 adap Reimbursement Of Research And Development Tax And Expenditure Credit
ReimbursementOfResearchAndDevelopmentTaxAndExpenditureCredit
19442000
CY2019 adap Reimbursement Of Research And Development Tax And Expenditure Credit
ReimbursementOfResearchAndDevelopmentTaxAndExpenditureCredit
18649000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
2505000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
2070000
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1904000
CY2021 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-5276000
CY2020 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-3836000
CY2019 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
185000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-158090000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-130092000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-137165000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-158090000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-130092000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-137165000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
934833017
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
854783763
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
629805218
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021 adap Number Of Contracts With Customer
NumberOfContractsWithCustomer
3
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6149000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3958000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1122000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
147330000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
52092000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
199422000
CY2021Q3 adap Collaboration Agreement Notice Period For Termination
CollaborationAgreementNoticePeriodForTermination
P180D
CY2021Q3 adap Collaboration Agreement Number Of Days Without Hsr Clearance After Effective Date Before Termination
CollaborationAgreementNumberOfDaysWithoutHsrClearanceAfterEffectiveDateBeforeTermination
P180D
CY2021Q3 adap Number Of Additional Terms
NumberOfAdditionalTerms
2
CY2021 adap Number Of Independent Targets
NumberOfIndependentTargets
2
CY2021 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
7424000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
149948000
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
219632000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1718000
CY2021 adap Concentration Risk Customers Number
ConcentrationRiskCustomersNumber
3
CY2021Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
752000
CY2020Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
139000
CY2021Q4 adap Receivables Past Due Amount
ReceivablesPastDueAmount
0
CY2021Q4 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
1.35
CY2021Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
30773000
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
20585000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9043000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6314000
CY2021Q4 adap Clinical Materials Current
ClinicalMaterialsCurrent
746000
CY2020Q4 adap Clinical Materials Current
ClinicalMaterialsCurrent
2086000
CY2021Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
2482000
CY2020Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
367000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2082000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
444000
CY2021Q4 adap Prepaid Expense And Other Assets Current Including Acounts Receivable
PrepaidExpenseAndOtherAssetsCurrentIncludingAcountsReceivable
45126000
CY2020Q4 adap Prepaid Expense And Other Assets Current Including Acounts Receivable
PrepaidExpenseAndOtherAssetsCurrentIncludingAcountsReceivable
29796000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
66747000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
58875000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
36253000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31097000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30494000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27778000
CY2021 us-gaap Depreciation
Depreciation
5630000
CY2020 us-gaap Depreciation
Depreciation
6627000
CY2019 us-gaap Depreciation
Depreciation
7172000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3132000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1000000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1730000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
937000
CY2020 us-gaap Lease Cost
LeaseCost
4403000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5051000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
4862000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4051000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
967000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
838000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
771000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
222000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
18000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
4259000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
4044000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
419000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
359000
CY2021 us-gaap Lease Cost
LeaseCost
4678000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
4101000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
3769000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y9M18D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.068
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.072
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3939000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4057000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3993000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4041000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
4090000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
12896000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
33016000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7548000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
25468000
CY2021Q3 adap Increase In Lease Liability And Corresponding Right Of Use Asset
IncreaseInLeaseLiabilityAndCorrespondingRightOfUseAsset
4290000
CY2021Q4 adap Reduction In Restricted Cash
ReductionInRestrictedCash
-2739000
CY2021Q3 us-gaap Payments For Rent
PaymentsForRent
1736000
CY2021Q4 adap Accrued Liabilities For Purchases Current
AccruedLiabilitiesForPurchasesCurrent
13436000
CY2020Q4 adap Accrued Liabilities For Purchases Current
AccruedLiabilitiesForPurchasesCurrent
13081000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11758000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11825000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4388000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2126000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
327000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
47000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29909000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27079000
CY2021Q4 adap Stockholders Equity Note Show Of Hands Votes Per Share
StockholdersEquityNoteShowOfHandsVotesPerShare
1
CY2021Q4 adap Stockholders Equity Note Show Of Hands Votes Per Share
StockholdersEquityNoteShowOfHandsVotesPerShare
1
CY2021Q4 adap Stockholders Equity Note Show Of Hands Votes Per Share
StockholdersEquityNoteShowOfHandsVotesPerShare
1
CY2021Q4 adap Stockholders Equity Note Show Of Hands Votes Per Share
StockholdersEquityNoteShowOfHandsVotesPerShare
1
CY2021Q4 adap Stockholders Equity Note Poll Votes Per Share
StockholdersEquityNotePollVotesPerShare
1
CY2021Q2 adap Stockholders Equity Note Authority Of Directors To Allot New Shares Or Grant Rights Maximum Aggregate Nominal Amount
StockholdersEquityNoteAuthorityOfDirectorsToAllotNewSharesOrGrantRightsMaximumAggregateNominalAmount
307869.00
CY2021Q2 adap Stockholders Equity Note Authority Of Directors To Allot Shares Or Grant Rights Without First Offering To Existing Shareholders Maximum Aggregate Nominal Amount
StockholdersEquityNoteAuthorityOfDirectorsToAllotSharesOrGrantRightsWithoutFirstOfferingToExistingShareholdersMaximumAggregateNominalAmount
307869.00
CY2021 adap Stock Issued Sales Agreement Remaining Amount Available For Sale
StockIssuedSalesAgreementRemainingAmountAvailableForSale
197360000
CY2015Q1 adap Share Based Compensation Arrangement By Share Based Payment Award Options Grants Maximum Value Per Participant
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumValuePerParticipant
30000
CY2015Q1 adap Share Based Compensation Arrangement By Share Based Payment Award Options Scheme Limit Grants Percentage Of Initial Fully Diluted Share Capital Immediately Following Initial Public Offering
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSchemeLimitGrantsPercentageOfInitialFullyDilutedShareCapitalImmediatelyFollowingInitialPublicOffering
0.08
CY2015Q1 adap Share Based Compensation Arrangement By Share Based Payment Award Options Scheme Limit Grants Automatic Annual Increase Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSchemeLimitGrantsAutomaticAnnualIncreasePercentage
0.04
CY2015Q1 adap Share Based Compensation Arrangement By Share Based Payment Award Options Schemes Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSchemesNumber
3
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
0.52
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5723646
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
11401390
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3549298
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
366000
CY2021 us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
862000
CY2020 us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
1265000
CY2019 us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
1488000
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
114915438
CY2021 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
18893000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2021 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
20629000
CY2020 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
10414000
CY2019 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
11053000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4321000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
8195000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1977000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
759000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5663000
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
60058450
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
0.66
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-157299000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-129930000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-136923000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
791000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
162000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
242000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
791000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
162000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
242000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
791000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
162000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
242000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
922000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
796000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1757000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
2009000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
238000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
156000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2917000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2961000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
15584000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
9292000
CY2021Q4 adap Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
2401000
CY2020Q4 adap Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
1745000
CY2021Q4 adap Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
2143000
CY2020Q4 adap Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
2343000
CY2020Q4 adap Deferred Tax Assets Operating Loss Carryforwards And Tax Credit Carryforwards
DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
71742000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
260000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
237000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
135360000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
85359000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
132443000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
82398000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2917000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2961000
CY2021 adap Valuation Allowance Deferred Tax Asset Foreign Currency Translation Adjustments
ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslationAdjustments
-1513000
CY2020 adap Valuation Allowance Deferred Tax Asset Foreign Currency Translation Adjustments
ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslationAdjustments
2897000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
132443000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
82398000
CY2021 adap Valuation Allowance Deferred Tax Asset Net Tax Expenses Relating To Continuing Operations
ValuationAllowanceDeferredTaxAssetNetTaxExpensesRelatingToContinuingOperations
50045000
CY2021 adap Operating Loss Carryforwards And Tax Credit Carryforward Annual Allowance
OperatingLossCarryforwardsAndTaxCreditCarryforwardAnnualAllowance
5000000
CY2021Q4 adap Operating Loss Carryforwards And Tax Credit Carryforward Percentage On Taxable Profit
OperatingLossCarryforwardsAndTaxCreditCarryforwardPercentageOnTaxableProfit
0.50
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 adap Deferred Tax Assets Operating Loss Carryforwards And Tax Credit Carryforwards
DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
114972000
CY2021Q4 us-gaap Noncurrent Assets
NoncurrentAssets
51369000
CY2020Q4 us-gaap Noncurrent Assets
NoncurrentAssets
46568000

Files In Submission

Name View Source Status
0001558370-22-003489-index-headers.html Edgar Link pending
0001558370-22-003489-index.html Edgar Link pending
0001558370-22-003489.txt Edgar Link pending
0001558370-22-003489-xbrl.zip Edgar Link pending
adap-20211231.xsd Edgar Link pending
adap-20211231x10k.htm Edgar Link pending
adap-20211231x10k001.jpg Edgar Link pending
adap-20211231x10k002.jpg Edgar Link pending
adap-20211231x10k003.jpg Edgar Link pending
adap-20211231x10k004.jpg Edgar Link pending
adap-20211231x10k005.jpg Edgar Link pending
adap-20211231x10k008.jpg Edgar Link pending
adap-20211231x10k_htm.xml Edgar Link completed
adap-20211231xex23d1.htm Edgar Link pending
adap-20211231xex31d1.htm Edgar Link pending
adap-20211231xex31d2.htm Edgar Link pending
adap-20211231xex32d1.htm Edgar Link pending
adap-20211231xex32d2.htm Edgar Link pending
adap-20211231xex4d4.htm Edgar Link pending
adap-20211231_cal.xml Edgar Link unprocessable
adap-20211231_def.xml Edgar Link unprocessable
adap-20211231_lab.xml Edgar Link unprocessable
adap-20211231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending